Axovant Sciences, LTD (AXON) shares had a brief spike in trading today, but gradually slid back to negative territory for the session. The company’s shares have been under consistent negative pressure since the second half of 2017, primarily due to persistent failures of the gene therapy treatments the company has researched. While the market is justifiably skeptical of the prospects that the company’s current pipeline might yield a successful result, the possibility still remains. Here’s a recap.
